# Table of Contents

## Highlights of This Issue

### SMALL MOLECULE THERAPEUTICS

3  **Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties**  
Liangxian Cao, Marla Weetall, Christopher Trocta, Katherine Cintron, Jiyuan Ma, Ming Jung Kim, Bansri Furia, Charles Romfo, Jason D. Gazi, Wencheng Li, Joshua Du, Josephine Sheedy, Jean Hedrick, Nicole Risher, Shirley Yeh, Hongyan Qi, Tamil Arasu, Seongwoo Hwang, William Lennox, Ronald Kong, Janet Petruska, Young-Choon Moon, John Babiak, Thomas W. Davis, Allan Jacobson, Neil G. Almstead, Art Branstrom, Joseph M. Colacino, and Stuart W. Peltz

17  **Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer**  
Frank Aboubakar Nana, Marylène Lecocq, Maha Zohra Ladjemi, Bruno Detry, Sébastien Dupasquier, Olivier Feron, Pierre P. Massion, Yves Sibille, Charles Pilette, and Sebahat Ocak

28  **ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity**  
Tim H. Holmström, Anna-Maartit Moilanen, Tarja Ikonen, Mari L. Björkman, Teo Linnanen, Gerdi Wohlfahrt, Stefan Karlsson, Rikka Okula, Timo Korjamo, Susanta Samajdar, Srinivasan Ramachandra, Rikka Okula, Timo Korjamo, Susanta Samajdar, Srinivasan Ramachandra, and Pekka J. Kallio

39  **Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells**  
Jun Dong, Zeyu Wu, Dan Wang, Laura E. Pascal, Joel B. Nelson, Peter Wipf, and Zhou Wang

51  **A Unique Nonsaccharide Mimetic of Heparin Hexasaccharide Inhibits Colon Cancer Stem Cells via p38 MAP Kinase Activation**  

### LARGE MOLECULE THERAPEUTICS

62  **Oleanolic Acid Inhibits Epithelial–Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization**  
Hongzhi Wang, Weilong Zhong, Jianmin Zhao, Heng Zhang, Qiang Zhang, Yuan Liang, Shuang Chen, Huijuan Liu, Shumin Zong, Yuxuan Tian, Honggang Zhou, Tao Sun, Yanrong Liu, and Cheng Yang

75  **Immune Effector Functions of Human IgG2 Antibodies against EGFR**  
Thies Rösner, Steffen Kahle, Francesca Montenegro, Hanke L. Matlugh, J.H. Marco Jansen, Mitchell Evers, Frank Beurskens, Jeanette H.W. Leusen, Timo K. van den Berg, and Thomas Valerius

89  **Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition**  
Haihong Zhong, Cui Chen, Ravinder Tammali, Shannon Breen, Jing Zhang, Christine Fazenbaker, Maureen Kennedy, James Conway, Brandon W. Higgs, Nicholas Holoweczkyj, Rajiv Raja, Jay Harper, Andrew J. Pierce, Ronald Herbst, and David A. Tice

100  **Anti-MET VH3 Pool Overcomes MET-Targeted Cancer Therapeutic Resistance**  
Zhipeng Su, Yunlu Han, Qichen Sun, Xiaoxiao Wang, Ting Xu, Wei Xie, and Xing Huang

### CANCER BIOLOGY AND TRANSLATIONAL STUDIES

112  **KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/Th90M in EGFR**  
Kaori Nakatani, Toshimitsu Yamaoka, Motoi Ohba, Ken-Ichi Fujita, Satoru Arata, Sojiro Kusumoto, Iori Taki-Takemoto, Daisuke Kamei, Shinichi Iwai, Junji Tsutsumi, and Tohru Ohmori

127  **Enhanced Antitumor Efficacy of Oncolytic Adenovirus–loaded Menstrual Blood–derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells**  
139 TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis
Sabrina Daniela da Silva, Bin Xu, Mariana Maschietto, Fabio Albaqueque Marchi, Maisa I. Alkailani, Krikor Bijian, Dinghizhang Xiao, and Moulay A. Alaoui-Jamali

147 Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer

162 PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

173 The Increased Expression of Estrogen-Related Receptor α Correlates with Wnt5a and Poor Prognosis in Patients with Glioma
Liudi Zhang, Yingfeng Zhu, Haixia Cheng, Jinsen Zhang, Yuqian Zhu, Haiwei Chen, Lu Chen, Huijie Qi, Guojiang Ren, Jianmin Tang, Mingkang Zhong, Wei Hua, Xiaojin Shi, and Qunyi Li

185 Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma

196 Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer
Tao Wei, Qi Zhang, Xiang Li, Wei Su, Guogang Li, Tao Ma, Shunliang Gao, Jianying Lou, Risheng Que, Lei Zheng, Xueli Bai, and Tingbo Liang

204 A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Jelmar Quist, Hasan Mirza, Maggie C.U. Cheang, Melinda L. Telli, Joyce A. O’Shaughnessy, Christopher J. Lord, Andrew N.J. Tutt, and Anita Grigoriadis

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

 MODELS AND TECHNOLOGIES

213 Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Steve Seung-Young Lee, Vytautas P. Bindokas, and Stephen J. Kron

227 Acknowledgment to Reviewers

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Toward examining impacts of the tumor microenvironment on cancer drug delivery, Lee and colleagues applied Transparent Tissue Tomography (T3) as a new tool to visualize macromolecules in situ. The cover is adapted from a detail of a T3 snapshot of immunotherapy, showing a section of tumor excised minutes after injecting anti-PD-L1. Antibody (red) flows through the microvasculature (CD31⁺, cyan) and extravasates to bind to its target (PD-L1, magenta) on cancer cells (Her2⁺, green), reactivating cytotoxic T lymphocytes (CD8⁺, yellow) to restore anti-tumor immune response. For details, see article on page 213.